Industry Symposia

Wednesday, 27 May 2015

SY 1

Natus Medical Inc.

Natus Medical Inc.

Fundamentals of aEEG in the neonatal population
Klebermaß-Schrehof Katrin (Austria)

aEEG in the HIE population and the effect of hypothermia on aEEG assessment
Schettler F. (Germany)

Practical application of aEEG

SY 2

Sarepta Therapeutics

Sarepta Therapeutics

Duchenne Muscular Dystrophy: Development of a Therapeutic Platform

Welcome and Introductions

Exon skipping as a clinical development platform
Cirak S. (Germany)

Clinical results: Baseline characteristics and eteplirsen 3.2 year data
Servais L. (France)

Questions and answer session

SY 3

Biogen

Biogen

Spinal Muscular Atrophy: Current challenges and novel therapeutic approaches on the horizon

SMA: the leading genetic cause of infant mortality
Mercuri E. (Italy)

Managing our SMA patients today: symptomatic treatment and supportive care
Goemans Nathalie (Belgium)

What might the future bring to our SMA patients: exploring upcoming treatment approaches
Muntoni F. (United Kingdom)

Panel discussion, summary and take-home messages

Thursday, 28 May 2015

SY 4

Novartis

Novartis

Medical Treatment of Neurological Manifestations in Patients with TSC - The Role of mTOR inhibitors

Welcome and Introduction
Feucht Martha (Austria)

Treatment of SEGA: Where does current clinical evidence take us?
Jozwiak S. (Poland)

Management of TSC-associated epilepsy: Current practice and unmet needs
Curatolo P. (Italy)

Panel discussion and closing remarks
Curatolo P. (Italy), Feucht Martha (Austria), Jozwiak S. (Poland)

SY 5

Actelion

Actelion

Niemann-Pick disease Type C and the paediatric patient: from first symptoms to treatment
Chair: Dionisi-Vici C. (Italy)

Welcome & introduction
Dionisi-Vici C. (Italy)

Screening, detection and diagnosis of NP-C in children
Dionisi-Vici C. (Italy)

NP-C: making a differential diagnosis in a heterogeneous disease
Ambegaonkar G. (United Kingdom)

NP-C and the paediatric patient: treatment and management of the disease
Lourenço C. (Brazil)

Q&A
All

Close
Dionisi-Vici C. (Italy)

SY 6

Cyberonics

Cyberonics

VNS Therapy® in children - The most Valuable Next Step in the treatment of your patients

Introduction
Feucht Martha (Austria)

Aligning goals and treatments
Lagae L. (Belgium)

Cardiac Based Seizure Response: addressing patients needs
Varadkar Sophie (United Kingdom)

Q&A and conclusion
Feucht Martha (Austria)

SY 7

PTC Therapeutics

PTC Therapeutics

Diagnosis and management of Duchenne muscular dystrophy: turning theory into practice

Welcome and introduction
Bernert G. (Austria)

Turning theory into practice: advances in the treatment of nonsense-mutation DMD
Mercuri E. (Italy)

Getting it right: diagnosis and treatment case study
Desguerre Isabelle (France)

Questions and meeting close
Bernert G. (Austria)

Friday, 29 May 2015

SY 8

Eisai

Eisai

Current challenges in childhood epilepsy

Introduction
Feucht Martha (Austria)

Diagnosis of cognitive and behavioural disorders in epilepsy
de Vries P. (South Africa)

Impact of epilepsy drugs on cognition and behaviour
Lagae L. (Belgium)

Management of seizures and comorbid disorders in generalized epilepsies
Feucht Martha (Austria)

Questions from audience and close
Feucht Martha (Austria)

SY 9

Pharm Allergan

Pharm Allergan

Treatment with Botulinum Toxin: Pain as a part of a widening spectrum
Chair: Heinen F. (Germany)

Mechanisms of Botulinum Toxin in Pain
Papavassiliou Antigone (Greece)

Cerebral Palsy & Pain - Why underrecognised?
Fairhurst C. (United Kingdom)

Migraine & Botulinumtoxin – What about adolescents?
Heinen F. (Germany)

SY 10

BIOMarin

Applying natural history knowledge and technological insights to evaluate clinical outcomes in DMD studies

Disease evolution in Duchenne muscular dystrophy: one year data from a prospective international multicentre natural history study
Goemans Nathalie (Belgium)

New understandings in the use of MRI in non-ambulant Duchenne Muscular Dystrophy boys
Ricotti Valeria (United Kingdom)

SY 11

Orphan Europe

Orphan Europe

Are you missing a treatable disorder? Homocystinurias in paediatric neurology
Chair: Morris A. (United Kingdom)

Introduction to the Homocystinurias
Morris A. (United Kingdom)

Classical Homocystinuria: a case presenting with neurological signs
Morris A. (United Kingdom)

Early neurological manifestations in remethylation disorders
Dionisi Vici C. (Italy)

Clinical guidance in child neurology: when to think homocysteine?
Schiff M. (France)